WecPost Postbiotics
Wider Applications
Stable Quality

Home > Products > WecPost Postbiotics > Lacticaseibacillus rhamnosus

Lacticaseibacillus rhamnosusLRa05

Potency

100B Cells/g


Source of Strain

Healthy infant intestines


Deposit Number

PTA-126815(ATCC) No.24377(CGMCC)
DSM34693(DSMZ)

Functions
  • Gastrointestinal Health
  • Metabolic Health
  • Emotional Health
  • Maternal & Child Health
  • Immune Health
  • Oral Health
References

[1]Sun M , Wu T , Zhang G , Liu R , Sui W , Zhang M , Geng J , Yin J , Zhang M . Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating the intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism. Food Funct. 2020 Nov 18;11(11):9514-9525. doi: 10.1039/d0fo01720e. PMID: 33063800.

[2]Wu T, Zhang Y, Li W, Zhao Y, Long H, Muhindo EM, Liu R, Sui W, Li Q, Zhang M. Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice. J Agric Food Chem. 2021 Aug 11;69(31):8797-8806. doi: 10.1021/acs.jafc.1c02925. Epub 2021 Aug 2. PMID: 34340304.

[3]Zhao TS, Xie LW, Cai S, Xu JY, Zhou H, Tang LF, Yang C, Fang S, Li M, Tian Y. Dysbiosis of Gut Microbiota Is Associated With the Progression of Radiation-Induced Intestinal Injury and Is Alleviated by Oral Compound Probiotics in Mouse Model. Front Cell Infect Microbiol. 2021 Oct 25;11:717636. doi: 10.3389/fcimb.2021.717636. PMID: 34760714; PMCID: PMC8573182.

[4]Gai Z, Dong Y, Xu F, Zhang J, Yang Y, Wang Y. Changes in the gut microbiota composition of healthy young volunteers after administration of Lacticaseibacillus rhamnosus LRa05: A placebo-controlled study. Front Nutr. 2023 Mar 14;10:1105694. doi: 10.3389/fnut.2023.1105694. PMID: 36998912; PMCID: PMC10043436.

[5]Gai Z, Liao W, Huang Y, Dong Y, Feng H, Han M. Effects of Bifidobacterium BL21 and Lacticaseibacillus LRa05 on gut microbiota in type 2 diabetes mellitus mice. AMB Express. 2023 Sep 16;13(1):97. doi: 10.1186/s13568-023-01603-1. PMID: 37716924; PMCID: PMC10505128.

[6]Dong Y, Han M, Fei T, Liu H, Gai Z. Utilization of diverse oligosaccharides for growth by Bifidobacterium and Lactobacillus species and their in vitro co-cultivation characteristics. Int Microbiol. 2023 Nov 9. doi: 10.1007/s10123-023-00446-x. Epub ahead of print. PMID: 37946011.

[7]Chen T, Shao Y, Zhang Y, Zhao Y, Han M, Gai Z. In vitro and in vivo genome-based safety evaluation of Lacticaseibacillus rhamnosus LRa05. Food Chem Toxicol. 2024 Apr;186:114600. doi: 10.1016/j.fct.2024.114600. Epub 2024 Mar 13. PMID: 38490350.

[8]Gu J, Chen Y, Wang J, Gao Y, Gai Z, Zhao Y, Xu F. Lacticaseibacillus rhamnosus LRa05 alleviated liver injury in mice with alcoholic fatty liver disease by improving intestinal permeability and balancing gut microbiota. Benef Microbes. 2024 Jul 3:1-13. doi: 10.1163/18762891-bja00022. Epub ahead of print. PMID: 38960385.

Specialization Advantages
  • 40,000+ Strain Resources
  • GRAS certified
  • Allergen free
  • SCI / Patent supported
  • Vegan friendly
  • Non-GMO verified
  • Clinically studied
  • Versatile use
  • Precise function
Industrialization Advantages
  • High potency
  • Low water activity
  • Cost-effectiveness
  • High stability
  • Fast delivery
  • cGMP standard
  • Excellent batch stability
  • Stable supply chain
  • Advanced equipment
Application
  • Dietary Supplement
  • Food
  • Dairy
  • Precision Medicine
  • Personal Care
  • Feed Additive/Pet
No. 999, Guangming Rd., Wujiang Economic and Technological Development Zone, Suzhou City, Jiangsu Province, China
Online Message